European Patients’ Academy on Therapeutic Innovation Ethical and practical challenges of organising clinical trials in small populations.

Slides:



Advertisements
Similar presentations
6th European Patients’ Rights Day The EMA Geriatric Medicines Strategy and the empowered aging patient Francesca Cerreta EMA (European Medicines Agency)
Advertisements

Areas of Research Specific issues. Clinical Trials Phase I First use in humans of an experimental drug or treatment In a small group of healthy volunteers.
Safety Reporting IN Clinical Trials
Susan Boynton, VP, Global Regulatory Affairs, Shire
NIHR Research Design Service London Enabling Better Research Forming a research team Victoria Cornelius, PhD Senior Lecturer in Medical Statistics Deputy.
Safety and Extrapolation Steven Hirschfeld, MD PhD Office of Cellular, Tissue and Gene Therapy Center for Biologics Evaluation and Research FDA.
429 pharmaceutical care Plan Refa’a AlAjmi. Goal of therpay A goal of therapy is the desired response or endpoint that you and your patient want to achieve.
Clinical trials Introduction.
Introduction Clinical trials Why clinical trials? The Clinical Trial Process Informed consent Patients‘ interests Rights and protection Trials Registers.
天 津 医 科 大 学天 津 医 科 大 学 Clinical trail. 天 津 医 科 大 学天 津 医 科 大 学 1.Historical Background 1537: Treatment of battle wounds: 1741: Treatment of Scurvy 1948:
Update on Therapies: Clinical Trials Timothy PM Whelan Assistant Professor of Medicine Medical Director, Interstitial Lung Disease Program University of.
Clinical Trials Medical Interventions
GCP compliance for GenISIS  This presentation is intended for clinical staff involved in recruiting patients to the GenISIS (Genetics of Influenza Susceptibility.
Use of Children as Research Subjects What information should be provided for an FP7 ethical review?
The ICH E5 Question and Answer Document Status and Content Robert T. O’Neill, Ph.D. Director, Office of Biostatistics, CDER, FDA Presented at the 4th Kitasato-Harvard.
Large Phase 1 Studies with Expansion Cohorts: Clinical, Ethical, Regulatory and Patient Perspectives Accelerating Anticancer Agent Development and Validation.
By Dr. Ahmed Mostafa Assist. Prof. of anesthesia & I.C.U. Evidence-based medicine.
Clinical Trials The Way We Make Progress Against Disease.
RANDOMIZED CLINICAL TRIALS. What is a randomized clinical trial?  Scientific investigations: examine and evaluate the safety and efficacy of new drugs.
Clinical Trials of Traditional Herbal Medicines In India Y.K.Gupta Professor & Head, Department of Pharmacology, All India Institute of Medical Sciences,
INCLUSION/EXCLUSION CRITERIA 1. The following are considerations when defining the cardiac arrest trial patient population (i.e., the inclusion/exclusion.
David A H Whiteman MD FAAP FACMG Global Clinical Sciences Leader Shire Pharmaceuticals.
Clinical Research Conference 2012 Legal, Ethical, and Social Dimensions of Clinical Research Takis Vidalis, Ph. D., Hellenic National Bioethics Commission.
Clinical Trials. What is a clinical trial? Clinical trials are research studies involving people Used to find better ways to prevent, detect, and treat.
Idara C.E.. Three ethical principles guides research with human participants. principle of Autonomy 1. The principle of Autonomy requires investigators.
Testing People Scientifically.  Clinical trials are research studies in which people help doctors and researchers find ways to improve health care. Each.
Summary About me & AMRC About the EU Clinical Trials Regulation – what’s new Implementation timeline What does this mean for UK ethicists?
Surrogate Endpoints and Correlative Outcomes Hem/Onc Journal Club January 9, 2009.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Evidence-Based Public Health Nancy Allee, MLS, MPH University of Michigan November 6, 2004.
Placebo-Controls in Short-Term Clinical Trials of Hypertension Sana Al-Khatib, MD, MHS Assistant Professor of Medicine Division of Cardiology Duke University.
Good Research, Bad Choices? Mary Coombs. What Makes Something Research Rather Than Treatment?
Copyright © 2013, 2009, and 2007, Pearson Education, Inc. Chapter 4 Gathering Data Section 4.3 Good and Poor Ways to Experiment.
An agency of the European Union Presented by: Paolo Tomasi Data Safety Monitoring Boards / Data Monitoring Committees in paediatric studies Paolo Tomasi,
Lecture 5 Objective 14. Describe the elements of design of experimental studies: clinical trials and community intervention trials. Discuss the advantages.
Introduction Clinical trials Why clinical trials? Process of a clinical trial Informed consent Patients‘ interests Rights and protection Study Registers.
What is a non-inferiority trial, and what particular challenges do such trials present? Andrew Nunn MRC Clinical Trials Unit 20th February 2012.
بسم الله الرحمن الرحيم جامعة أم درمان الإسلامية كلية الطب و العلوم الصحية - قسم طب المجتمع مساق البحث العلمي / الدفعة 21 Basics of Clinical Trials.
How To Design a Clinical Trial
Considerations for Topical Microbicide Phase 3 Trial Designs, an Investigator’s Perspective Andrew Nunn Medical Research Council Clinical Trials Unit London,
Idara C.E.. Three ethical principles guides research with human participants. principle of Autonomy 1. The principle of Autonomy requires investigators.
Understanding Clinical Trials – Part 2 Georgianne Arnold, MD Professor of Pediatrics University of Pittsburgh Medical Center Pittsburgh Children’s Hospital.
Pilot and Feasibility Studies NIHR Research Design Service Sam Norton, Liz Steed, Lauren Bell.
European Patients’ Academy on Therapeutic Innovation The Purpose and Fundamentals of Statistics in Clinical Trials.
HPTN Ethics Guidance for Research: Community Obligations Africa Regional Working Group Meeting, May 19-23, 2003 Lusaka, Zambia.
European Patients’ Academy on Therapeutic Innovation Aspects of pharmacovigilance: Post-Authorisation Efficacy Studies (PAES)
European Patients’ Academy on Therapeutic Innovation Blinding in clinical trials.
© 2010 Jones and Bartlett Publishers, LLC. Chapter 12 Clinical Epidemiology.
Evidence-Based Mental Health PSYC 377. Structure of the Presentation 1. Describe EBP issues 2. Categorize EBP issues 3. Assess the quality of ‘evidence’
European Patients’ Academy on Therapeutic Innovation Challenges in Personalised Medicine.
Off-label Use.
A capacity building programme for patient representatives
How To Design a Clinical Trial
Patient Focused Drug Development An FDA Perspective
PAEDIATRIC REGULATION
Evidence-based Medicine
Enrolling in Clinical Trials
Community Participation in Research
REGULATORY PROBLEMS IN CARING OUT PRE- AND POST- AUTHORISATION CLINICAL TRIALS Dr Penka Decheva GCP Inspector, BDA.
Within Trial Decisions: Unblinding and Termination
Randomized Trials: A Brief Overview
Clinical Study Results Publication
Concepts of Paediatric Investigation Plans (PIP)
Bozeman Health Clinical Research
Critical Reading of Clinical Study Results
Strategies for Implementing Flexible Clinical Trials Jerald S. Schindler, Dr.P.H. Cytel Pharmaceutical Research Services 2006 FDA/Industry Statistics Workshop.
Regulatory perspective
Strength of Evidence; Empirically Supported Treatments
Tim Auton, Astellas September 2014
Greg Nezat CRNA, PhD CDR/NC/USN Chairman, IRB II
Presentation transcript:

European Patients’ Academy on Therapeutic Innovation Ethical and practical challenges of organising clinical trials in small populations

European Patients’ Academy on Therapeutic Innovation  There is no common definition of small populations. A ‘small population’ is generally referred to when only a limited overall number of patients with the disease being studied exist.  There is some overlap between small and special populations. Small populations can include:  rare diseases including specific sub-types of more common diseases  children (paediatric patients)  elderly (geriatric patients) Small populations in clinical trials 2

European Patients’ Academy on Therapeutic Innovation  30 million people in the EU are affected by rare diseases.  Rare diseases are those occurring in less than 1 in 2,000 people.  Ultra rare disease occurs in less than 1 in 2,000,000 people (suggested prevalence 1 ).  There is limited knowledge on rare diseases, due to less research (limited research interest and funding available)  Rare diseases may show a large variability of disease expression and disease state. Rare and ultra rare diseases 1 Hennekam, R.C. (2011). Care for patients with ultra-rare disorders. European Journal of Medical Genetics, 54(3), doi: /j.ejmg

European Patients’ Academy on Therapeutic Innovation  In principle, the development of orphan medicinal products and medicines for children are regarded as standard situations, in other words, guidelines exist to regulate them.  In these situations, medicines development follows the principles of evidence-based medicine, as in common diseases.  The development of orphan medicinal products and medicines for children may limit what is possible and reasonable.  Development may therefore require non-standard solutions. Standard and non-standard situations 4

European Patients’ Academy on Therapeutic Innovation  The value of clinical study results should be considered in relation to the levels of evidence, as the results of some kinds of studies are more significant than others: 5 Levels of evidence

European Patients’ Academy on Therapeutic Innovation  Key questions:  Is it possible to do a randomised controlled trial (RCT)?  Is a small RCT better than a larger observational study?  Risk of bias?  How accurate will the result be?  What evidence is needed for initial marketing authorisation?  What evidence is needed post-marketing? What level of evidence can you obtain in studies in small populations and in children? 6

European Patients’ Academy on Therapeutic Innovation Full development with randomised controlled trials (RCT), compared with placebo and/or reference therapy Common or rare disease, reference therapy available Full development including RCT compared with placebo or standard of treatment Open-label, non-comparative trials? Common or rare disease, no reference therapy available SituationSolution Standard Non- standard 7

European Patients’ Academy on Therapeutic Innovation Situations and solutions Small populations Enough for RCT Only small Phase II trials Not enough for RCT Unconventional study design Non-comparator trials Historical control Standard Non- standard 8

European Patients’ Academy on Therapeutic Innovation The Committee for Medicinal Products for Human Use (CHMP) has given guidelines for these studies:  small populations ( ific_guideline/2009/09/WC pdf) ific_guideline/2009/09/WC pdf  paediatric population ( ific_guideline/2009/09/WC pdf) ific_guideline/2009/09/WC pdf Availability of guidelines for studies in small populations 9

European Patients’ Academy on Therapeutic Innovation  Standardised data collection – planned in advance (prospectively), documented in protocol, and adhered to:  Maximising collection of important information  Keeping study participation burden acceptable  Avoiding loss-to-follow-up  Best use should be made of animal models of disease. Studies in small populations: Key factors (1) 10

European Patients’ Academy on Therapeutic Innovation Key factors:  Understanding the natural course of disease, how this may change over time.  Understanding sources of possible misinterpretation of data (confounders).  Understanding sources of variable response to therapy. Studies in small populations: Key factors (2) 11

European Patients’ Academy on Therapeutic Innovation  Typically, efficacy is measured in terms of:  Cure  Survival  Time to disease progression  Progression-free survival  Reversal of organ dysfunction  Disease stabilisation  Selection of the most suitable endpoint is crucial. Studies in small populations: Evaluating efficacy (1) 12

European Patients’ Academy on Therapeutic Innovation  How is efficacy measured?  Hard endpoints (for instance, survival rates)  Surrogate endpoints (clinical improvement)  Symptom relief  Quality of life  Biomarker, surrogate value unknown Studies in small populations: Evaluating efficacy (2) Often a logical combination of measures pointing to the same conclusion must be considered. 13

European Patients’ Academy on Therapeutic Innovation Studies in small populations: Choosing a comparator 14 What is the most appropriate comparator? Placebo or standard of treatment?Available therapy = active comparator? What is an acceptable comparator? Historical control group?No control group? What is the desired outcome? Superior efficacy?Non-inferior efficacy? ‘Clearly effective’ although no control group available

European Patients’ Academy on Therapeutic Innovation  Seamless adaptive design:  Phase II and Phase III are combined in one study  design is adapted as trial is ongoing  best dose levels are continued after the interim analyses  Sequential studies:  it enrols patients and analyses until a reliable conclusion is made  effect/outcome emerges rapidly  Modeling:  effect of parameters  relationship efficacy - effects Examples of study designs 15

European Patients’ Academy on Therapeutic Innovation  Finding relevant trials can be a challenge  Long commutes to the investigator’s site might be required  Possible relocation of the patient may be required  Financial support and/or access to health care system may be required  Need for language support  Need for teaching/school facilities for children  Reorganisation of family life may be required Practical problems for patients in a rare disease trial 16

European Patients’ Academy on Therapeutic Innovation  All measures are taken to protect privacy during clinical trials. However, this is a challenge in rare or ultra rare diseases due to:  smaller patient registries or non-existence of patient registries  risk of being identified in a clinical trial Privacy and transparency 17

European Patients’ Academy on Therapeutic Innovation  Benefit-risk assessment due to the life-threatening disease condition  A known effective comparator is often not available  New treatment may not be accessible after the end of the trial  No established process for providing trial results to patients Ethical issues in clinical trials with rare diseases 18

European Patients’ Academy on Therapeutic Innovation  Patients may not be able to give informed consent themselves and may rely on the decision of the legal representative who may not always represent the patient’s own opinion.  The decision to participate in the trial is often not really voluntary because there may be no treatment alternative.  Placebo control is a particular problem due to the severity of the disease, requiring that the participant agree to possibly not receiving any treatment during the initial trial phase. Informed consent process 19

European Patients’ Academy on Therapeutic Innovation  A balance must be found between what is necessary and what is possible.  Methods are available to show efficacy in clinical trials in small populations.  The development strategy for treatment in small populations should be discussed in advance with regulators in scientific advice/protocol assistance.  Clinical trials in rare or ultra rare diseases present a number of ethical and organisational challenges. Conclusion 20